Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable angina~* candidates to drug eluting stent implantation~* High on-treatment platelet reactivity according to a point-of-care platelet function test~Exclusion Criteria:~* chronic therapy with statins~* inability to provide informed consent~* intolerance to statins~* acute or chronic liver failure or ALT \> 2 times ULN~* known myopathy~* CKD stage IV or dialysis treatment~* pregnancy or breast-feeding~* malignancy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin-Clopidogrel group (Type: EXPERIMENTAL): Patients who receive Atorvastatin 80 mg/day and Clopidogrel 150 mg/day
- Clopidogrel group (Type: ACTIVE_COMPARATOR): Patients who receive clopidogrel 150 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).